Up Therapeutics LLC

[Not Yet Scheduled]
Up Therapeutics, LLC (UpTx) is a biotech company focused on improving the effectiveness of cancer therapies by targeting the Ubiquitin-Proteasome system. Using rational design, in vitro screening, testing, and in vivo animal studies, the company has discovered a promising novel lead compound,
Up284, which targets the RPN13 receptor for proteasome substrates. Up284 effectively kills various cancers in a cell culture system and in animal models with a promising safety profile. Up284 shows promising for treating cancers of various types, including ovarian, prostate, multiple myeloma, triple negative breast cancer, and glioblastoma.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
RPN13 inhibitor
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
Professor
PapiVax